SCHEMBL826360

SCHEMBL826360

O=C(Nc1cccc(O)c1)C(F)(F)F

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.67
KMT2A Q03164 4/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
MEN1 O00255 2/20 0.59
MAPT P10636 2/20 0.59
LMNA P02545 1/20 0.59
BAZ1A Q9NRL2 1/20 0.59
CYP1A2 P05177 2/20 0.59
ALDH1A1 P00352 1/20 0.59
NLRP3 Q96P20 2/20 0.54
TP53 P04637 2/20 0.50
MAOB P27338 1/20 0.50
MAPK1 P28482 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
MMP1 P03956 3/20 0.49
MMP2 P08253 3/20 0.49
MMP9 P14780 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20981664 0.88 L3MBTL1 (0.82) L3MBTL1NPC1RAB9AMAPTCYP1A2
SCHEMBL29659984 0.81 L3MBTL1 (0.67) L3MBTL1KMT2ANPC1RAB9AMEN1
SCHEMBL5546915 0.81 L3MBTL1 (0.67) L3MBTL1KMT2ANPC1RAB9AMEN1
SCHEMBL1131584 0.81 NPSR1 (0.67) L3MBTL1KMT2ANPC1RAB9AMEN1
SCHEMBL11871933 0.81 ALDH1A1 (0.59) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL2883710 0.80 MAPT (0.68) L3MBTL1KMT2ARAB9AMEN1MAPT
SCHEMBL21133073 0.80 L3MBTL1 (0.65) L3MBTL1KMT2ANPC1RAB9AMEN1
SCHEMBL1820057 0.80 L3MBTL1 (0.65) L3MBTL1NPC1RAB9AMAPTCYP1A2
SCHEMBL5545392 0.80 L3MBTL1 (0.65) L3MBTL1KMT2ANPC1RAB9AMEN1
SCHEMBL2723870 0.80 L3MBTL1 (0.65) L3MBTL1NPC1RAB9AMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116102537-A Quinolinone derivative and preparation method and application thereof 四川大学 2023-05-12 CN disclosed
US-10808127-B2 Color conversion with solid matrix films and green rhodamines MOLECULED LTD. (IL) 2020-10-20 US disclosed
US-10465110-B2 Rhodamine based salts StoreDot Ltd. (IL) 2019-11-05 US disclosed
US-10227492-B2 Modifications of the sol-gel films and production processes thereof StoreDot Ltd. (IL) 2019-03-12 US disclosed
US-20180105696-A1 COLOR CONVERSION WITH SOLID MATRIX FILMS AND GREEN RHODAMINES StoreDot Ltd. (IL) 2018-04-19 US disclosed
US-20180072892-A1 MODIFICATIONS OF THE SOL-GEL AND PROCESS THEREOF StoreDot Ltd. (IL) 2018-03-15 US disclosed
US-20180037738-A1 COLOR CONVERSION WITH SOLID MATRIX FILMS StoreDot Ltd. (IL) 2018-02-08 US disclosed
US-20180039131-A1 CONTROL OF ILLUMINATION SPECTRA FOR LCD DISPLAYS StoreDot Ltd. (IL) 2018-02-08 US disclosed
EP-3210966-A1 ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Acucela, Inc. (US) 2017-08-30 EP disclosed
US-8497274-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-30 US disclosed
US-20120214855-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 US disclosed
US-8143258-B2 Benzothiazole compounds useful for Raf inhibition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-27 US disclosed
EP-2358689-A1 Benzothiazole derivatives as anticancer agents Takeda Pharmaceutical Company Limited (JP) 2011-08-24 EP disclosed
US-20100216810-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 US disclosed
WO-2010064722-A1 BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-10 WO disclosed
US-6764829-B2 DETECTING PARASITES USING CHROMOGENIC SUBSTRATES; OBTAIN SAMPLE, INCUBATE WITH CHROMGENIC SUBSTRATE, DETECT FORMATION OF CHROMOPHORE PRODUCT ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2004-07-20 US disclosed
US-20020132263-A1 Enzyme detection/assay method and substrates NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-09-19 US disclosed
US-6379911-B2 ANALYZING NUCLEOSIDE HYDROLASES; DETECTING PARASITES ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2002-04-30 US disclosed
US-20010019823-A1 ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2001-09-06 US disclosed
WO-1997031008-A1 ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES INDUSTRIAL RESEARCH LIMITED (NZ) 1997-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010019823-A1 ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES PNP, TREH, XDH L3MBTL1 2218/4885KMT2A 4064/4885NPC1 3012/4885
US-20120214855-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 L3MBTL1 3413/4885KMT2A 1093/4885NPC1 4128/4885
US-20100216810-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 L3MBTL1 3413/4885KMT2A 1093/4885NPC1 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.